KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accounts Payables (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Accounts Payables data on record, last reported at $939.0 million in Q4 2025.

  • For Q4 2025, Accounts Payables rose 18.94% year-over-year to $939.0 million; the TTM value through Dec 2025 reached $939.0 million, up 18.94%, while the annual FY2025 figure was $939.0 million, 18.94% up from the prior year.
  • Accounts Payables reached $939.0 million in Q4 2025 per REGN's latest filing, up from $903.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $939.0 million in Q4 2025 and bottomed at $427.0 million in Q3 2021.
  • Average Accounts Payables over 5 years is $613.5 million, with a median of $561.7 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: dropped 13.37% in 2022, then surged 81.74% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $427.0 million in 2021, then skyrocketed by 37.99% to $589.2 million in 2022, then rose by 2.95% to $606.6 million in 2023, then skyrocketed by 30.15% to $789.5 million in 2024, then rose by 18.94% to $939.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $939.0 million in Q4 2025, $903.8 million in Q3 2025, and $723.9 million in Q2 2025.